Logo Biosynex

Biosynex

On Soin et Nature, discover Biosynex, a French expert in medical devices and rapid diagnostic tests for prevention, screening, and daily health monitoring. With reliable, innovative, and clinically validated products, Biosynex facilitates fast, safe, and accessible care for everyone.

More details
Filter
Number of products : 15
Sort
Sort
Close

Biosynex: Your Partner in Rapid Diagnostics

Specializing in the design and distribution of rapid diagnostic tests, the French laboratory Biosynex has established itself since 2005 as a key player in more than 90 countries. With a mission to improve overall patient care, Biosynex provides healthcare professionals with reliable, innovative solutions tailored to every need.

Since its founding, Biosynex has developed a collaborative approach by working closely with pharmacists, physicians, diagnostic laboratories, and hospitals. This close relationship with healthcare providers ensures high-performance products that facilitate prevention, screening, and the implementation of appropriate treatments.

To remain at the forefront, Biosynex invests in advanced technological tools and collaborates with renowned institutions, enabling the company to address modern challenges while anticipating the needs of tomorrow. The devices undergo rigorous testing to ensure their accuracy, safety, and compliance with international standards (ISO 13485:2016).

With more than 550 employees dedicated to healthcare, Biosynex stands out as a trusted partner serving professionals and patients. Each product embodies the values of excellence and commitment that have built the company’s reputation.

An Innovative and Proactive Company

Biosynex continually pushes the boundaries of rapid diagnostics. Through an ambitious intellectual property policy, the laboratory files its own patents to protect its innovations. This strategy ensures high-value-added products that meet the specific needs of the global market.

Biosynex’s innovations span a wide range of fields, from rapid screening tests (for home or laboratory use) to women’s health, treatment monitoring, and medical assistive devices. The goal? To meet the needs of healthcare professionals while simplifying patients’ lives through accurate and accessible solutions.

Biosynex’s international expansion is supported by a strategy of targeted acquisitions. These transactions enable the laboratory to diversify its expertise while strengthening its presence in strategic markets such as the United States and Europe. By investing in cutting-edge technologies and strategic partnerships, Biosynex is committed to remaining a leader in the in vitro diagnostics industry.

Biosynex is committed to making its innovations accessible through a variety of channels: pharmacies, hospitals, supermarkets, and more. The laboratory meets a wide range of needs through a broad and adaptable product line, while complying with the medical sector’s strict regulations. This commitment to public health reflects a clear mission: to make early and accurate diagnosis a reality for everyone.

The laboratory has also adopted a sustainable approach by optimizing its manufacturing processes and incorporating environmentally friendly practices. In this way, Biosynex demonstrates that medical research and environmental ethics can go hand in hand.

Biosynex Product Lines: A Comprehensive Offering

Biosynex offers solutions tailored to every specific need. Here is an overview of the available product lines:

  • Dry Eye: Following the acquisition of INNOXA Laboratories, Biosynex offers care and prevention products to relieve the symptoms of dry eye.
  • Biotherapy Monitoring: With the integration of PROCISEDX and CHEMBIO DIAGNOSTICS, Biosynex offers advanced solutions for monitoring and evaluating drug treatments.
  • Advanced DNA Testing: The isothermal technology resulting from the acquisition of ENALEES enables precise detection of pathogens through DNA amplification.
  • Connected Health: Through DOC2U and AVALUN, Biosynex offers connected medical devices for self-monitoring and portable diagnostics.
  • Mosquito Repellents: With PARAKITO, discover natural solutions to prevent bites, available in more than 5,000 pharmacies in France.
  • European Pharmaceutical Products: The integration of BIGIX PHARMA and VISIOMED enables Biosynex to expand its pharmaceutical portfolio with products tailored to the European market.

Each product line is designed to address specific medical needs, ensuring reliable solutions tailored to the daily lives of patients and healthcare professionals. These diverse product lines reflect Biosynex’s ongoing commitment to being a comprehensive and essential player in rapid diagnostics.

Strategic Development and Key Innovations

Biosynex’s success is partly based on its ability to expand its reach through strategic acquisitions. For example:

  • The acquisition of CHEMBIO DIAGNOSTICS marks a major milestone in Biosynex’s expansion into the North American market, the largest for the in vitro diagnostics industry.
  • The acquisition of VISIOMED strengthened the pharmaceutical division with a broader network in France and internationally.
  • The collaboration with ENALEES brings innovative technology to infection screening through isothermal DNA amplification.

These initiatives not only strengthen Biosynex’s position in the global market but also its ability to innovate and meet the expectations of healthcare professionals and patients.

Why Choose Biosynex?

With Biosynex, you benefit from cutting-edge expertise and quality guaranteed by strict standards. The laboratory’s commitment to controlling the entire value chain enables it to offer reliable, accurate products tailored to every medical need. If you’re looking for effective and accessible solutions, Biosynex is the obvious choice for optimized health and rapid diagnosis.

The laboratory embodies a clear vision: that of healthcare accessible to all, where innovation and responsibility go hand in hand. Choosing Biosynex means placing your trust in a company dedicated to improving your quality of life.